Rabeprazole sodium enteric-coated tablets

DRUG3 trials

Sponsors

TenNor Therapeutics (Suzhou) Limited, TenNor Therapeutics Inc., Nanjing First Hospital, Nanjing Medical University

Conditions

DepressionFunctional DyspepsiaH.Pylori InfectionHelicobacter Pylori Infection

Phase 1

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

CompletedNCT06337604

TenNor Therapeutics Inc.Helicobacter Pylori Infection

Start: 2017-10-10End: 2017-11-23Updated: 2024-04-01

Phase 3

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

CompletedNCT05857163

TenNor Therapeutics (Suzhou) LimitedH.Pylori Infection

Start: 2023-05-18End: 2024-03-26Updated: 2025-08-17

Unknown Phase

Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression

Not yet recruitingNCT06481371

Nanjing First Hospital, Nanjing Medical UniversityDepression, Functional Dyspepsia

Start: 2024-06-30End: 2025-04-30Target: 120Updated: 2024-07-01

Related Papers

Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.

2025-09-102 citations